Skip to main content
. 2021 Sep 12;2021(9):CD011612. doi: 10.1002/14651858.CD011612.pub3

NCT03965871.

Methods Randomised, multiple dose, placebo‐controlled, double‐blind, multicentre study
Participants 88 participants with bipolar depression
Interventions Drug: esketamine DPI ‐ low dose
Drug: esketamine DPI ‐ medium dose
Drug: esketamine DPI ‐ high dose
Drug: placebo DPI
Outcomes MADRS
Response
Remission
Time to relapse
C‐SSRS
BPRS
YMRS
Adverse events
Notes Trial completed February 2021, no results available yet.